FDA 510(k)
FDA class 2
Substantially Equivalent
🇺🇸 United States
Access TSH (3rd IS) Assay, DxI 9000 Access Immunoassay Analyzer
K Number: K221225
·
Decision Nov 10, 2022
Classifications
1
FEI Numbers
73
Registration Numbers
73
Same Product Code
241
Applicant Total
270
Review Days
196
Research this 510(k) in seconds
The Research Assistant summarizes clearance history, predicates and product-code trends — and cites every record.
Free to try · every answer cites its records
Basic Information
- Device Name
- Access TSH (3rd IS) Assay, DxI 9000 Access Immunoassay Analyzer
- K Number
- K221225
- Device Class
- FDA class 2
- Clearance Type
- Traditional
- Regulation Number
- 862.1690
- Medical Specialty
- Clinical Chemistry
- Decision
- Substantially Equivalent
- Statement or Summary
- Summary
- Applicant
- Beckman Coulter, Inc.
- Date Received
- April 28, 2022
- Decision Date
- November 10, 2022
- Product Code
- JLW
- Advisory Committee
- Clinical Chemistry
- Review Advisory Committee
- CH
- Third Party
- N
Classifications
This FDA 510(k) entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| JLW | Radioimmunoassay, Thyroid-Stimulating Hormone | FDA class 2 | Clinical Chemistry |
Similar 510(k) Clearances
Other 510(k) clearances with the same product code (JLW), ordered by most recent decision date.
Atellica® IM TSH3-Ultra II (TSH3ULII)
FDA 510(k)
FDA Class 2
·Clinical Chemistry
Dimension LOCI Thyroid Stimulating Hormone Flex reagent cartridge (TSHL); Dimension LOCI Free Thyroxine Flex reagent cartridge (FT4L)
FDA 510(k)
FDA Class 2
·Clinical Chemistry
Maverick Diagnostic System TC1000; Maverick Test Panel A0.B0
FDA 510(k)
FDA Class 2
·Clinical Chemistry
ADVIA Centaur® TSH3-Ultra II (TSH3ULII)
FDA 510(k)
FDA Class 2
·Clinical Chemistry
Atellica® CI Analyzer, Atellica® IMThyroid Stimulating Hormone 3-Ultra (TSH3-UL), Atellica® CH Albumin BCP (AlbP)
FDA 510(k)
FDA Class 2
·Clinical Chemistry
Elecsys TSH
FDA 510(k)
FDA Class 2
·Clinical Chemistry
Other Clearances by Beckman Coulter, Inc.
| K Number | Device Name | ||
|---|---|---|---|
| K252169 | Access BNP II | Mar 24, 2026 | Substantially Equivalent |
| K254059 | Access anti-HBc IgM | Mar 13, 2026 | Substantially Equivalent |
| K253687 | Access anti-HBc Total | Feb 19, 2026 | Substantially Equivalent |
| K251995 | Access anti-HAV IgM | Jan 27, 2026 | Substantially Equivalent |
| K250588 | Access Rubella IgG | Nov 17, 2025 | Substantially Equivalent |
| K252580 | iQ200 Series | Sep 10, 2025 | Substantially Equivalent |
| K243846 | Access anti-HAV | Sep 9, 2025 | Substantially Equivalent |
| K243804 | MicroScan Dried Gram-Negative MIC/Combo Panels with Cefepime (CPE) (0.12-64 µg/mL) (MicroScan) | Aug 20, 2025 | Substantially Equivalent |
| K250036 | MicroScan Dried Gram-Positive MIC/Combo Panels with Daptomycin (DAP) (0.06-32 µg/mL) | Aug 15, 2025 | Substantially Equivalent |
| K243483 | Access hsTnI | Aug 1, 2025 | Substantially Equivalent |